Abstract Details
Marc Bigaud
PRESENTER |
Marc Bigaud has received personal compensation for serving as an employee of Novartis Pharma. |
Daniel Anthony, PhD, MA (University of Oxford) | Dr. Anthony has received personal compensation for serving as an employee of University of Oxford. Dr. Anthony has received personal compensation for serving as an employee of Somerville College Oxford. Dr. Anthony has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Anthony has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Neuroplast. Dr. Anthony has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Oxomics. The institution of Dr. Anthony has received research support from Numares. The institution of Dr. Anthony has received research support from MRC UK. |
No disclosure on file | |
Tatjana Uffelmann | No disclosure on file |
No disclosure on file | |
No disclosure on file | |
Barbara Nuesslein-Hildesheim, PhD (Novartis Pharma AG) | Dr. Nuesslein-Hildesheim has received personal compensation for serving as an employee of Novartis Pharma AG. Dr. Nuesslein-Hildesheim has stock in Novartis Pharma AG. |
Bernd C. Kieseier, MD (Novartis) | Dr. Kieseier has received personal compensation for serving as an employee of Novartis. Dr. Kieseier has stock in Novartis. |